氟西汀治疗帕金森病伴发抑郁的临床研究

Clinical research on fluoxetine treating Parkinson's disease with depression

目的探讨应用氟西汀药物治疗帕金森病(PD)伴发抑郁后的临床疗效及安全性。方法收集我院的PD患者共100例进行抑郁自评量表(SDS)、Haimihon抑郁量表(HAMD)的评定后,筛选出抑郁症患者64例,随机分为治疗组(n=32)和对照组(n=32),治疗组患者予氟西汀治疗,对照组予以帕金森常规药物治疗,于治疗后的第2、4、6周末进行疗效及安全性评定。结果治疗后,治疗组抑郁治疗有效率及PD治疗有效率均优于对照组,且差异有统计学意义(P<0.01)。两组不良反应均较轻,SERS各因子发生率及总分比较差异无统计学意义(P>0.05)。结论氟西汀对治疗伴有抑郁症状的PD患者有效,且安全性好。

[Objective] To investigate the clinical efficacy and safety of Fluoxetine in the treatment of Parkinson disease （PD）. [Methods ] 100 patients with PD were assessed by Haimihon Depression Rating Scales （HAMD）, Serf- Rating Depression Scale（SDS）. After assessing, 64 patients with depression were randomly divided into control group （n ：32） and therapy group （n =32）. The therapy group was treated with Fluoxetine and the control group was treated with usual therapy. Then the curative and side effects in the all patients were assessed at the end of the 2nd ,4th and 6th weeks after the initiation of the study. [Results] There was significant difference in the total effective rate of and-depression and anti-PD in the control group and the therapy group （P 〈0.01）. The side effects in the two groups were slight, and the incidences of all the factors in SERS between the two groups had no significant differences （P 〉 0.05）. [ Conclusions] Fluoxetine is effective and safe in adjuvant treatment of PD accompanied by depression.